posted on 2010-06-16, 13:38authored byDanijela Markovic, R. A. John Challiss
The G protein-coupled receptors (GPCRs) are a superfamily of transmembrane receptors that have a broad distribution and can collectively recognise a diverse array of ligands. Activation or inhibition of GPCR signalling can affect many (patho)physiological processes, and consequently they are a major target for existing and emerging drug therapies. A common observation has been that the pharmacological, signalling and regulatory properties of GPCRs can differ in a cell- and tissue-specific manner. Such “phenotypic” diversity might be attributable to post-translational modifications and/or association of GPCRs with accessory proteins, however, post-transcriptional mechanisms are also likely to contribute. Although approximately 50% of GPCR genes are intronless, those that possess introns can undergo alternative splicing, generating GPCR subtype isoforms that may differ in their pharmacological, signalling and regulatory properties. In this review we shall highlight recent research into GPCR splice variation and discuss the potential consequences this might have for GPCR function in health and disease.
History
Citation
Cellular and Molecular Life Sciences, 2009, 66 (20), pp. 3337-3352.
This is the author's final draft of the paper published as Cellular and Molecular Life Sciences, 2009, 66 (20), pp. 3337-3352. The original publication is available at www.springerlink.com. Doi: 10.1007/s00018-009-0093-4